- Report
- February 2025
- 200 Pages
Global
From €4019EUR$4,490USD£3,424GBP
- Report
- June 2025
- 383 Pages
Global
From €5237EUR$5,850USD£4,461GBP
- Report
- March 2025
- 150 Pages
Global
From €2909EUR$3,250USD£2,478GBP
€4342EUR$4,850USD£3,698GBP
- Report
- April 2025
- 150 Pages
Global
From €2909EUR$3,250USD£2,478GBP
€4342EUR$4,850USD£3,698GBP
- Drug Pipelines
- April 2025
- 70 Pages
Global
From €1343EUR$1,500USD£1,144GBP
- Report
- May 2025
- 184 Pages
Global
From €3174EUR$3,545USD£2,703GBP
€3526EUR$3,939USD£3,004GBP
- Report
- May 2025
- 188 Pages
Global
From €3174EUR$3,545USD£2,703GBP
€3526EUR$3,939USD£3,004GBP
- Report
- May 2025
- 198 Pages
Global
From €3174EUR$3,545USD£2,703GBP
€3526EUR$3,939USD£3,004GBP
- Report
- May 2025
- 184 Pages
Global
From €3174EUR$3,545USD£2,703GBP
€3526EUR$3,939USD£3,004GBP
- Report
- May 2025
- 191 Pages
Global
From €3174EUR$3,545USD£2,703GBP
€3526EUR$3,939USD£3,004GBP
- Report
- February 2025
- 200 Pages
Global
From €4019EUR$4,490USD£3,424GBP
- Report
- December 2024
- 200 Pages
Global
From €2238EUR$2,500USD£1,906GBP
- Report
- June 2025
- 266 Pages
Global
From €5237EUR$5,850USD£4,461GBP
- Report
- June 2025
- 391 Pages
Global
From €5237EUR$5,850USD£4,461GBP
- Report
- August 2024
- 137 Pages
Global
From €2685EUR$2,999USD£2,287GBP
- Report
- November 2024
- 203 Pages
Global
From €3984EUR$4,450USD£3,393GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1343EUR$1,500USD£1,144GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1790EUR$2,000USD£1,525GBP
- Report
- July 2024
- 100 Pages
Global
From €3357EUR$3,750USD£2,859GBP
- Report
- January 2025
- 183 Pages
Global
From €3424EUR$3,825USD£2,917GBP
€4028EUR$4,500USD£3,431GBP

The Carbapenem market is a subset of the Antibiotics market, which is composed of drugs used to treat bacterial infections. Carbapenems are a class of antibiotics that are used to treat serious infections caused by bacteria that are resistant to other antibiotics. They are typically used as a last resort when other antibiotics have failed. Carbapenems are generally well-tolerated and have a low risk of side effects.
Carbapenems are used to treat a wide range of infections, including pneumonia, urinary tract infections, and skin and soft tissue infections. They are also used to treat infections caused by multidrug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA).
The Carbapenem market is highly competitive, with several major players. These include Merck & Co., Pfizer, GlaxoSmithKline, AstraZeneca, and Sanofi. Other companies in the market include Allergan, Novartis, and Daiichi Sankyo. Show Less Read more